KLF4 and cancer: The inability of ORP100S to boost KLF4 in cancer cells could be related to the previously‐reported inability of Cys35 TRX mutants to stimulate proliferation in cancer cells,[38] as well as differences in uptake or cancer cells’ altered signaling environment.